Overview

Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo-Controlled Phase-III STudy

Status:
Terminated
Trial end date:
2016-08-29
Target enrollment:
Participant gender:
Summary
To evaluate and compare the efficacy and safety of regorafenib versus placebo in subjects with colorectal cancer (CRC) after curative resection of liver metastasis and completion of all planned chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Bayer